Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With HyperkalaemiaRecruiting
NCT03813407Phase 3Updated Jul 20, 2026
Sponsor: AstraZeneca
Hyperkalaemia
United States, Brazil, Canada, China, Germany +8 more
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in RussiaRecruiting
NCT07390240N/AUpdated Jul 20, 2026
Sponsor: AstraZeneca
Hypophosphatasia
Russia
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis DiagnosisRecruiting
NCT06978660N/AUpdated Jul 20, 2026
Sponsor: Idoven 1903 S.L.
Transthyretin Cardiac Amyloidosis
United States, France, Germany, Spain, United Kingdom
AZD9291 in Combination With Ascending Doses of Novel TherapeuticsActive Not Recruiting
NCT02143466Phase 1Updated Jul 20, 2026
Sponsor: AstraZeneca
Advanced Non Small Cell Lung Cancer
United States, Canada, Japan, Poland, Russia +3 more
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)Recruiting
NCT07221253Phase 3Updated Jul 20, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
United States, Australia, Belgium, Brazil, Canada +14 more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)Recruiting
NCT06103864Phase 3Updated Jul 20, 2026
Sponsor: AstraZeneca
Breast Cancer
United States, Argentina, Australia, Brazil, Canada +19 more
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityRecruiting
NCT07013643Phase 1Updated Jul 20, 2026
Sponsor: AstraZeneca
Healthy Participants
United States
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsRecruiting
NCT06932263Phase 2Updated Jul 20, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, Brazil, Chile, China +16 more
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Not Yet Recruiting
NCT07711002Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Canada
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Recruiting
NCT06380738N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
Germany
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaActive Not Recruiting
NCT05692180Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, France, Italy, Poland +4 more
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruiting
NCT05835310Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Canada, China +12 more
A Phase 2 Study of ABSK043 Combined With OsimertinibNot Yet Recruiting
NCT07710612Phase 2Updated Jul 17, 2026
Sponsor: Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
China
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR AmyloidosisRecruiting
NCT06355934N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
ATTR Amyloidosis
United States, Canada, China, Denmark, Germany +6 more
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsActive Not Recruiting
NCT06194448Phase 2Updated Jul 17, 2026
Sponsor: AstraZeneca
Lung Cancer
United States, China, Israel, South Korea, Spain +4 more
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological MalignanciesActive Not Recruiting
NCT04395079Phase 2Updated Jul 17, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Metastatic Malignant Female Reproductive System Neoplasm · Platinum-Resistant Malignant Female Reproductive System Neoplasm · Recurrent Malignant Female Reproductive System Neoplasm · Refractory Malignant Female Reproductive System Neoplasm
United States
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerActive Not Recruiting
NCT03423628Phase 1Updated Jul 17, 2026
Sponsor: AstraZeneca
Recurrent Glioblastoma Multiforme · Primary Glioblastoma Multiforme · Brain Neoplasms, Malignant · Leptomeningeal Disease (LMD)
United States, Japan, United Kingdom
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive Not Recruiting
NCT03732677Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Muscle Invasive Bladder Cancer
United States, Australia, Belgium, Brazil, Canada +17 more
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseRecruiting
NCT06314282N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus (SLE)
Argentina, China, Costa Rica, Egypt, Guatemala +7 more
ALICIA (Acalabrutinib in CLL Therapy)Completed
NCT04746950N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
Russia
Observational Study Protocol: LIVER-RRecruiting
NCT06252753N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Hepatobiliary Cancers
United States, Australia, Austria, Belgium, Brazil +17 more
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in SpainActive Not Recruiting
NCT06746116Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Advanced or Recurrent Endometrial Cancer
Spain
Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)Recruiting
NCT06705764Phase 4Updated Jul 17, 2026
Sponsor: University of Alberta
Severe Asthma
Canada
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruiting
NCT05123482Phase 1, Phase 2Updated Jul 16, 2026
Sponsor: AstraZeneca
Breast Cancer · Biliary Tract Carcinoma · Ovarian Cancer · Endometrial Cancer
United States, Australia, Belgium, Canada, China +10 more
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor PatientsRecruiting
NCT07404202N/AUpdated Jul 16, 2026
Sponsor: AstraZeneca
Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
China

Previous page Next page